← Back to all trials
Recruiting
NCT05106387
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
Conditions: Chronic Kidney Disease (CKD)
Sex: All
Ages: 18 Years – 70 Years
Healthy volunteers: No
Enrollment: 20
Sponsor: Regeneron Pharmaceuticals
Location: Cedars-Sinai Medical Center Los Angeles California
Summary
The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347).
No study drug will be given during this study.
Eligibility Criteria
Inclusion Criteria:
1. Received at least 1 dose of treatment with vonsetamig in study R5459-RT-1944 \[NCT05092347\].
2. Received after acceptable crossmatching, a kidney transplant while enrolled in study R5459-RT-1944
3. Willing and able to comply with clinic visits and study-related procedures
4. Provide informed consent signed by study patient or legally acceptable representative
Exclusion Criteria:
1.There are no exclusion criteria for this study.
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Source: ClinicalTrials.gov (NCT05106387). StuddyBuddy aggregates publicly available trial information.
